Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a slight dose change boost IVF embryo success?

NCT ID NCT07772375

Disease control Sponsor: Vietnam Military Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests whether a higher starting dose of follicle-stimulating hormone (FSH) improves embryo development in women undergoing IVF. Participants with good fertility prognosis are randomly assigned to receive either 225 IU or 300 IU of FSH daily during ovarian stimulation. The main goal is to see if the dose affects the rate of blastocyst formation, with other outcomes including egg quality and fertilization. The results could help refine dosing protocols for IVF.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Follicle-stimulating hormone (FSH) given as a daily injection, at either 225 IU or 300 IU, during ovarian stimulation for IVF.
What this could lead to
If successful, this could help doctors choose the best starting FSH dose for women with good fertility prognosis, potentially improving IVF success rates and reducing side effects.
What could go wrong
This is a single trial, and results may not apply to all women. The optimal dose may vary by individual, and higher doses could increase the risk of ovarian hyperstimulation syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 380 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 34 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patient or oocyte donor aged \<35 years. * Body mass index (BMI) between 18 and 25 kg/m². * Normal ovarian reserve, defined by: * Antral follicle count (AFC) ≥8 on ultrasound; and * AMH level between 1.5 and 4.5 ng/mL. * First IVF treatment cycle. * Controlled ovarian stimulation using a progestin-primed ovarian stimulation (PPOS) protocol with recombinant FSH and dydrogesterone. * Indication for in vitro fertilization using intracytoplasmic sperm injection (ICSI). * Indication for extended embryo culture to the blastocyst stage. * Willingness to participate in the study and provision of written informed consent. Exclusion Criteria: * Polycystic ovary syndrome (PCOS) diagnosed according to the Rotterdam criteria, currently referred to as polyendocrine metabolic ovarian syndrome (PMOS). * Structural abnormalities of the ovaries. * Ovarian endometriosis. * Medical or gynecological conditions that may affect ovarian response to controlled ovarian stimulation. * Indication for luteinizing hormone (LH) supplementation during controlled ovarian stimulation. * Poor sperm quality, cryptozoospermia, surgically retrieved sperm (PESA, TESE, or microTESE), cryopreserved sperm, or donor sperm. * Indication for artificial oocyte activation (AOA) or rescue ICSI (R-ICSI).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility (ivf patients) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility (ivf patients) Infertility assisted reproductive technology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • An Sinh Hospital

    Ho Chi Minh City, Ho Chi Minh City, 722210, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.